BCMA-Targeted Treatments Boost Responses in Relapsed/Refractory Myeloma
Published: Monday, Mar 16, 2020
Noopur S. Raje, MD
Preliminary data with BCMA-directed antibody-drug conjugates (ADCs), bispecific T-cell engagers (BiTEs), and CAR T-cell therapy have demonstrated the importance of targeting BCMA in multiple myeloma, according to Noopur S. Raje, MD.
... to read the full story